Leerink Swann downgrades Arena Pharmaceuticals (Nasdaq: ARNA) to Market Perform. Price target $6.

Leerink analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE